Rare Impact



QUÉ ES NUEVO EN EURORDIS?

EURORDIS lidera la nueva iniciativa RARE-IMPACT para identificar los retos y soluciones para mejorar el acceso de los pacientes a las terapias génica y celular

Gene and cell therapies offer ground-breaking new opportunities for patients with rare and complex diseases.

Maximizing patient access to effective gene and cells therapies is a part of the Rare Impact initiative's mission.

30 million Europeans are living with rare diseases and 80% of rare diseases are genetic in origin.

There are many challenges hampering patients’ access to gene and cell therapies; to date, the availability of these therapies is limited.

 Gene and cell therapy availability – Feb '19

• Withdrawn from market
• Available in > 3 European markets
• Available in < 3 European markets

EURORDIS has initiated a patient-focused collaboration that seeks to improve patients’ access to these therapies.